Prevalence of weakness and factors mediating discrepancy between reported and observed leg weakness in people with sciatica
European Spine Journal · 2024
DOI: 10.1007/s00586-024-08330-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Spine Journal, 2024. Verfasst von Lucy Dove und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, The University of Oxford, West Wing Level 6, Oxford, OX3 9DU, UK. Hauptthemen laut MEDLINE: Sciatica, Muscle Weakness. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NIHR Oxford Biomedical Research Centre, Wellcome Trust Career Development Fellowship.
Abstract (Originalsprache)
Purpose
To establish the prevalence and agreement between reported and observed leg weakness in people with sciatica. To establish which factors mediate any identified difference between reported and observed leg weakness in people with sciatica.
Methods
68 people with a clinical diagnosis of sciatica, records from spinal service, secondary care NHS Hospital, England, UK reviewed. Primary outcome measures were the sciatica bothersome index for reported leg weakness and the Medical Research Council scale for observed weakness. Agreement was established with Cohen’s Kappa and intraclass correlation coefficient. Potential factors that may mediate a difference between reported and observed weakness included leg pain, sciatica bothersome index sensory subscale, age, hospital anxiety and depression subscale for anxiety.
Results
85% of patients reported weakness but only 34% had observed weakness. Cohen’s Kappa (0.066, 95% CI − 0.53, 0.186; p = 0.317)] and ICC 0.213 (95% CI − 0.26, 0.428, p = 0.040) both showed poor agreement between reported and observed weakness. The difference between reported and observed measures of weakness was mediated by the severity of leg pain (b = 0.281, p = 0.024) and age (b = 0.253, p = 0.042).
Conclusion
There is a high prevalence of reported leg weakness in people with sciatica, which is not reflected in observed clinical measures of weakness. Differences between reported and observed weakness may be driven by the severity of leg pain and age. Further work needs to establish whether other objective measures can detect patient reported weakness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, The University of Oxford, West Wing Level 6, Oxford, OX3 9DU, UK.
- Oxford Spinal Surgery Unit, Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
- Integrated Pain and Spinal Service (IPASS), Berkshire Healthcare NHS Foundation Trust, Berkshire, UK.
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, The University of Oxford, West Wing Level 6, Oxford, OX3 9DU, UK. annina.schmid@neuro-research.ch.
Förderung
- Medical Research Council
- NIHR Oxford Biomedical Research Centre
- Wellcome Trust Career Development Fellowship
- MRF
- Wellcome Trust
- Medical Research Foundation
Zitieren
APA
Dove, L., Baskozos, G., Kelly, T., Buchanan, E., & Schmid, A. B. (2024). Prevalence of weakness and factors mediating discrepancy between reported and observed leg weakness in people with sciatica. European Spine Journal. https://doi.org/10.1007/s00586-024-08330-6
Vancouver
Dove L, Baskozos G, Kelly T, Buchanan E, Schmid AB. Prevalence of weakness and factors mediating discrepancy between reported and observed leg weakness in people with sciatica. European Spine Journal. 2024. doi:10.1007/s00586-024-08330-6
BibTeX
@article{Dove2024,
author = {Dove, Lucy and Baskozos, Georgios and Kelly, Thomas and Buchanan, Elaine and Schmid, Annina B},
title = {Prevalence of weakness and factors mediating discrepancy between reported and observed leg weakness in people with sciatica},
journal = {European Spine Journal},
year = {2024},
doi = {10.1007/s00586-024-08330-6}
}
EUVIMED